Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial hypertension drug trial. Winrevair is the first activin-signaling inhibitor therapy ...

Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the ...

Merck (NYSE:MRK) stock in focus as the company partners with Jiangsu Hengrui in a $2B deal for heart disease therapy HRS-5346 ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

Merck will pay the Chinese pharma company $200 million upfront and up to $1.77 billion in development, regulatory, and commercial milestone payments.